Fossil Remedies

MARCH 29, 2022

It is every entrepreneur’s dream to launch a business that earns a great profit. After all that is something, which everyone aims for. The pharma business has become one of the most popular businesses in the last 20 years. Why? It is because the pharma sector has done remarkably well. Also, it shows signs of good growth in the next few years. If you consider a few data facts, then the pharma sector today around 40+ Billion dollars , and in the next few years, it will cross even 100 Billion dolla

98

98

Outsourcing Pharma

MARCH 29, 2022

The agency's requested funding for FY 2023, nearly 34% higher than for FY 2022, calls for investments in public health modernization and pandemic preparation.

FDA 92

FDA 92

pharmaphorum

MARCH 29, 2022

With the rapid onset of the pandemic, the race to develop a viable vaccine quickly became a race to secure access to the developed vaccines. In this article, Ben Hargreaves examines how wealth determined the winners and what is now underway to help lower-income countries gain access to the available vaccines. At the beginning of the pandemic, there were two principal issues facing producing an effective vaccine: how can one be quickly developed, and how can production meet global demand?

Vaccines 79

Vaccines Generic Medicine 79

Outsourcing Pharma

MARCH 29, 2022

A leader from the healthcare technology company discusses the conflictâs impact on the region and beyond and the need to better guard against interruptions.

93

93

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Board Vitals - Pharmacist

MARCH 29, 2022

Our lives are often divided into chapters, delineated by specific transition points. Much like blood flowing through our circulatory system, the trajectory of our lives can be turbulent at times while laminer at others. It can advance and progress, but can also be met with opposition and obstruction. It is in those watershed moments when we recall a notable difference, a growth.

Medical Schools 52

Medical Schools 52

NF2 BioSolutions

MARCH 29, 2022

– Everyone’s journey with NF2 is different. No 2 cases are the same. The biggest problem we face is the ‘unknown’ and never knowing what’s around the corner for us. After being diagnosed and going through a whirlwind of emotions. I decided to start looking into new activities/hobbies to try, looking for something physical so that I could try and keep my body strong and active. – – Ice hockey is something that I’d always wanted to try, but was never

52

52

Pharma Mirror

MARCH 29, 2022

Karlsruhe/Germany, Romaco Macofar’s Oftalmica was specially developed for aseptic filling of sterile eye drops, nasal sprays and injectables. Meeting all GMP requirements for safe processing of highly viscous, oily and foaming liquids, the machine additionally offers fast format changes and short cleaning times. The Oftalmica is Romaco Macofar’s latest technology for aseptic filling of sterile eye drops.

52

52

Pharma Marketing Network

MARCH 29, 2022

Tune in to this episode of the Pharma marketing Podcast, with our guest Wendy Pease, President of Rapport International and the author of The Language of Global Marketing for a conversation on why pharma should be thinking global from the start, addressing how to keep a consistent brand globally, and the many things that need to be considered when curating your global market.

52

52

Pharma Mirror

MARCH 29, 2022

NIEL, BELGIUM, eTheRNA Manufacturing, a specialist RNA process developer and manufacturing member of the Belgian eTheRNA group, is introducing a new Lipid Nanoparticle (LNP) formulation development and production service to support the discovery and early pre-clinical development of RNA-based therapeutics and vaccines. This new LNP service uses eTheRNA’s proprietary lipid libraries and proprietary formulations to facilitate targeted delivery and tailored biodistribution solutions.

Vaccines 52

Vaccines 52

pharmaphorum

MARCH 29, 2022

What do 300 million people have in common? They are living with rare diseases that are defined by their scarcity within the general population. In the United States, this means fewer than one in 1,500 people; in the EU, fewer than one in 2,000. That is 5% of the world’s population. The rarity of these diseases means information about them is scarce, as there are often too few people in a geographic location to inform experts fully or to complete a clinical trial.

52

52

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Pharma Times

MARCH 29, 2022

Collaboration will involve the development of new class IgM antibodies with a view to gaining market approval

44

44

pharmaphorum

MARCH 29, 2022

Less than six months after the late-stage failure of tofersen, Biogen and Ionis have suffered further disappointment in the amyotrophic lateral sclerosis (ALS) pipeline after BIIB078 (IONIS-C9Rx) failed to demonstrate clinical benefit in a Phase 1 trial. In the randomised, placebo-controlled, dose-escalating trial, researchers evaluated the efficacy of the investigational antisense oligonucleotide BIIB078 as a treatment for adults with C9orf72-associated ALS.

49

49

Pharma Times

MARCH 29, 2022

Charter for Change examines reasons for inequalities and sets out recommendations to improve diabetes care

43

43